Skip links


Celia has 13 years of experience in Private Equity and has been part of the team since 2005, in charge of the Life Sciences sector and the Supernova 2 Fund.

Before this, she held management and product development positions at Cambridge Antibody Technology (Medimmune since its purchase by Astra Zeneca), one of the most successful UK biotechnology companies.

She was involved in the development of several therapeutic antibodies in collaboration with international biotechnology or pharmaceutical partners.
Celia holds a degree in Chemistry from the University of Geneva (Switzerland), a Ph.D. Chemistry from the University of Oxford (UK) and an MBA from Grenoble Ecole de Management (France).

She sits on the board of companies including Algaia, Bioaxial, Diabeloop, Enobraq, Keranova, Theranexus and Uromems.

Supernova Invest team